| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCAN |
| Uniprot No | Q96GW7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-911aa |
| 氨基酸序列 | MAQLFLPLLAALVLAQAPAALADVLEGDSSEDRAFRVRIAGDAPLQGVLGGALTIPCHVHYLRPPPSRRAVLGSPRVKWTFLSRGREAEVLVARGVRVKVNEAYRFRVALPAYPASLTDVSLALSELRPNDSGIYRCEVQHGIDDSSDAVEVKVKGVVFLYREGSARYAFSFSGAQEACARIGAHIATPEQLYAAYLGGYEQCDAGWLSDQTVRYPIQTPREACYGDMDGFPGVRNYGVVDPDDLYDVYCYAEDLNGELFLGDPPEKLTLEEARAYCQERGAEIATTGQLYAAWDGGLDHCSPGWLADGSVRYPIVTPSQRCGGGLPGVKTLFLFPNQTGFPNKHSRFNVYCFRDSAQPSAIPEASNPASNPASDGLEAIVTVTETLEELQLPQEATESESRGAIYSIPIMEDGGGGSSTPEDPAEAPRTLLEFETQSMVPPTGFSEEEGKALEEEEKYEDEEEKEEEEEEEEVEDEALWAWPSELSSPGPEASLPTEPAAQEESLSQAPARAVLQPGASPLPDGESEASRPPRVHGPPTETLPTPRERNLASPSPSTLVEAREVGEATGGPELSGVPRGESEETGSSEGAPSLLPATRAPEGTRELEAPSEDNSGRTAPAGTSVQAQPVLPTDSASRGGVAVVPASGDCVPSPCHNGGTCLEEEEGVRCLCLPGYGGDLCDVGLRFCNPGWDAFQGACYKHFSTRRSWEEAETQCRMYGAHLASISTPEEQDFINNRYREYQWIGLNDRTIEGDFLWSDGVPLLYENWNPGQPDSYFLSGENCVVMVWHDQGQWSDVPCNYHLSYTCKMGLVSCGPPPELPLAQVFGRPRLRYEVDTVLRYRCREGLAQRNLPLIRCQENGRWEAPQISCVPRRPARALHPEEDPEGRQGRLLGRWKALLIPPSSPMPGP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与BCAN重组蛋白相关的参考文献摘要(文献标题及内容为模拟示例)：
---
1. **标题**：*Recombinant human brevican core protein modulates glioma cell adhesion and motility*
**作者**：Smith, J. et al.
**摘要**：本研究通过大肠杆菌系统表达了人源BCAN核心蛋白的重组片段(氨基酸1-400)，验证其糖基化非依赖性功能。实验表明，该重组蛋白能抑制胶质瘤细胞迁移，并通过整合素信号通路影响细胞外基质黏附。
2. **标题**：*Structural characterization of brevican using recombinant expression in mammalian cells*
**作者**：Nakamura, M. et al.
**摘要**：利用HEK293细胞表达系统获得全长BCAN重组蛋白，结合质谱和圆二色谱分析其三维结构。结果表明，BCAN的N端结构域对神经元突触的可塑性具有调控作用，为研究其在神经退行性疾病中的机制提供依据。
3. **标题**：*BCAN-mediated interactions between neural stem cells and the extracellular matrix*
**作者**：Viapiano, M.S. et al.
**摘要**：通过昆虫杆状病毒系统制备重组BCAN蛋白，发现其通过硫酸软骨素链与神经干细胞表面受体Syndecan-1结合，显著促进干细胞分化为少突胶质细胞，提示其在神经再生中的潜在应用价值。
---
注：以上文献信息为示例性模拟，实际引用需以真实发表的论文数据为准。建议通过PubMed或Web of Science以“brevican recombinant protein”为关键词检索最新研究。
Brevican (BCAN) is a member of the lectican family of chondroitin sulfate proteoglycans, which includes aggrecan, versican, and neurocan. Primarily expressed in the central nervous system (CNS), BCAN is enriched in the brain, particularly in neurons and oligodendrocytes. Its structure features an N-terminal hyaluronan-binding domain, a central chondroitin sulfate glycosaminoglycan (CS-GAG) attachment region, and a C-terminal lectin-like domain. These domains enable BCAN to interact with hyaluronan, tenascin-R, and other extracellular matrix (ECM) components, contributing to neural tissue organization, synaptic plasticity, and axonal guidance during development.
BCAN plays dual roles in CNS homeostasis and pathology. In healthy brains, it stabilizes perisynaptic ECM structures, modulates cell adhesion/migration, and supports neuroprotection. However, dysregulated BCAN expression or proteolytic processing is implicated in neurological disorders. For instance, BCAN undergoes cleavage by proteases like ADAMTS-4/5 in Alzheimer’s disease and traumatic brain injury, releasing bioactive fragments that may exacerbate neuroinflammation or disrupt ECM integrity. In gliomas, BCAN overexpression correlates with tumor invasiveness, as its cleaved forms promote cancer cell migration via interactions with integrin receptors.
Recombinant BCAN proteins, produced in mammalian or bacterial expression systems, are vital tools for studying these mechanisms. They enable precise analysis of BCAN’s structural domains, glycosylation patterns, and protease susceptibility. Researchers also utilize recombinant BCAN to model ECM remodeling in vitro, screen therapeutic agents targeting lectican pathways, or engineer biomimetic scaffolds for neural repair. Its role as a biomarker or therapeutic target in neurodegeneration and cancer continues to drive interest in BCAN-related biotechnology applications.
×
